Immune-Mediated Thrombocytopenia in Dogs: Welfare Guide

Key Welfare Considerations

• ITP involves immune-mediated destruction of platelets causing profound thrombocytopenia and bleeding welfare risk.
• Clinical welfare signs include petechiae, ecchymoses, spontaneous bleeding from mucous membranes, and haematuria.
• Platelet counts below 30,000/μL indicate significant welfare spontaneous bleeding risk.
• Primary ITP has no identifiable underlying cause — immune dysregulation is the welfare mechanism.
• Secondary ITP from infections, neoplasia, or drugs requires welfare treatment of the underlying cause.
• Prednisolone at immunosuppressive welfare doses is the cornerstone of ITP treatment.
• Vincristine injection accelerates platelet release from megakaryocytes — emergency welfare benefit.
• Human IV immunoglobulin provides rapid platelet welfare recovery in severe refractory cases.
• Azathioprine or ciclosporin are welfare adjuncts for refractory or steroid-resistant ITP.
• Activity restriction prevents trauma-induced welfare bleeding during acute thrombocytopenia.
• Blood transfusion provides temporary welfare red cell support when haemorrhage causes anaemia.
• Platelet-rich plasma transfusion provides minimal welfare benefit — platelets are rapidly destroyed.
• Doxycycline treatment addresses tick-borne disease welfare contribution when infectious cause is possible.
• Welfare monitoring through serial platelet counts guides treatment response and dose adjustments.
• Relapse rates are significant — long-term welfare monitoring continues after initial remission.